Nestle and Seres Collaborate to Jointly Commercialize SER-109 for Recurrent Clostridioides difficile Infection

Shots:

• Seres to receive $175M up front, $125M upon the US FDA’s approval of SER-109 along with ~$225M as a commercial milestone. Seres will be responsible for development & pre-commercialization costs in the US and will be entitled to 50% of the commercial profits
• The agreement includes co-commercialization of microbiome therapeutics in the US and Canada representing the expansion of an existing strategic collaboration between the companies. NHS has commercial rights to Seres’ investigational drug for CDI and IBD outside of the US and Canada
• If approved, SER-109 would be the first-ever FDA-approved microbiome therapeutic

Click here to­ read full press release/ article | Ref: Business Wire | Image: PR Newswire UK